Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET scan agent shows promise for spotting prostate cancer

NCT ID NCT04838626

Completed Diagnosis Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new imaging agent called [18F]CTT1057 for PET scans to see how well it can find prostate cancer tumors. 195 men with high-risk prostate cancer who were scheduled for surgery received the scan. The results were compared to tissue samples taken during surgery to measure accuracy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

  • Explorer Molecular Imaging center

    Sacramento, California, 95816, United States

  • Novartis Investigative Site

    Marseille, 13273, France

  • Novartis Investigative Site

    Nîmes, 30029, France

  • Novartis Investigative Site

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    Toulouse, 31054, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Bergamo, BG, 24127, Italy

  • Novartis Investigative Site

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    Milan, MI, 20141, Italy

  • Novartis Investigative Site

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Bellinzona, 6500, Switzerland

  • Novartis Investigative Site

    Geneva, 1211, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.